Search Results for: NPHP1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel BCL2L11 BCL2 like 11
  • Activation of BIM and translocation to mitochondria
  • BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
  • NRAGE signals death through JNK
  • Signaling by BRAF and RAF fusions
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • RUNX3 regulates BCL2L11 (BIM) transcription
  • FLT3 Signaling
  • FOXO-mediated transcription of cell death genes
Novel COX5B cytochrome c oxidase subunit 5B
  • TP53 Regulates Metabolic Genes
  • Respiratory electron transport
  • Cholic Acid
  • N-Formylmethionine
ADAM15 ADAM metallopeptidase domain 15
  • Degradation of the extracellular matrix
  • Invadopodia formation
ARHGAP32 Rho GTPase activating protein 32
  • Rho GTPase cycle
BCAR1 BCAR1 scaffold protein, Cas family member
  • Downstream signal transduction
  • p130Cas linkage to MAPK signaling for integrins
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
FBXO7 F-box protein 7
  • Neddylation
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Parkinson's disease (PD)
FLNA filamin A
  • Platelet degranulation
  • GP1b-IX-V activation signalling
  • Cell-extracellular matrix interactions
  • RHO GTPases activate PAKs
  • OAS antiviral response
  • Artenimol
  • Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
  • Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia
  • Periventricular nodular heterotopia (PVNH)
  • FG syndrome (FGS); Opitz-Kaveggia syndrome
FLNB filamin B
  • ISG15 antiviral mechanism
  • Spondylocarpotarsal synostosis syndrome
  • FLNB-related disorders, including: ; Atelostogenesis, type I; Boomerang dysplasia; Atelosteogenesis, type III; Larsen syndrome
FLNC filamin C
  • Cell-extracellular matrix interactions
  • Myofibrillar myopathies (MFM), including: Desminopathy (MFM1); alpha-B Crystallinopathy (MFM2); Myotilinopathy (MFM3); Zaspopathy (MFM4); Filaminopathy (MFM5); Bag3opathy
INVS inversin
  • Nephronophthisis-medullary cystic kidney disease, including; Nephronophthisis (NPH) ; Nephronophthisis-like nephropathy 1; Medullary cystic kidney disease 1; Medullary cystic kidney disease 2 (MSKD2)
KHDRBS1 KH RNA binding domain containing, signal transduction associated 1
  • PTK6 Regulates Proteins Involved in RNA Processing
NPHP3 nephrocystin 3
  • Trafficking of myristoylated proteins to the cilium
  • Senior-Loken syndrome
  • Renal-hepatic-pancreatic dysplasia
  • Nephronophthisis-medullary cystic kidney disease, including; Nephronophthisis (NPH) ; Nephronophthisis-like nephropathy 1; Medullary cystic kidney disease 1; Medullary cystic kidney disease 2 (MSKD2)
  • Meckel syndrome (MKS); Meckel-Gruber syndrome
NPHP4 nephrocystin 4
  • Signaling by Hippo
  • Anchoring of the basal body to the plasma membrane
  • Senior-Loken syndrome
  • Nephronophthisis-medullary cystic kidney disease, including; Nephronophthisis (NPH) ; Nephronophthisis-like nephropathy 1; Medullary cystic kidney disease 1; Medullary cystic kidney disease 2 (MSKD2)
PAK2 p21 (RAC1) activated kinase 2
  • Nef and signal transduction
  • Generation of second messenger molecules
  • Regulation of PAK-2p34 activity by PS-GAP/RHG10
  • Regulation of activated PAK-2p34 by proteasome mediated degradation
  • Stimulation of the cell death response by PAK-2p34
  • FCERI mediated MAPK activation
  • FCERI mediated MAPK activation
  • CD28 dependent Vav1 pathway
  • Ephrin signaling
  • Sema3A PAK dependent Axon repulsion
  • Activation of RAC1
  • VEGFA-VEGFR2 Pathway
  • Smooth Muscle Contraction
  • VEGFR2 mediated vascular permeability
  • CD209 (DC-SIGN) signaling
  • RHO GTPases activate PAKs
  • RHO GTPases activate PAKs
  • MAPK6/MAPK4 signaling
  • Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
  • Fostamatinib
PTK2B protein tyrosine kinase 2 beta
  • Signal regulatory protein family interactions
  • VEGFA-VEGFR2 Pathway
  • Interleukin-2 signaling
  • Leflunomide
  • Genistein
  • 4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide
  • Baricitinib
  • Fostamatinib
TNK2 tyrosine kinase non receptor 2
  • ATP
  • Debromohymenialdisine
  • Entrectinib
  • Fostamatinib
TUBB tubulin beta class I
  • Regulation of PLK1 Activity at G2/M Transition
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • Neutrophil degranulation
  • AURKA Activation by TPX2
  • Potential therapeutics for SARS
  • Vinorelbine
  • Vincristine
  • Vinblastine
  • Podofilox
  • Colchicine
  • Epothilone D
  • Patupilone
  • CYT997
  • CA4P
  • ZEN-012
  • Tirbanibulin
  • Copper
  • Artenimol
  • Vinflunine
  • Depatuxizumab mafodotin
  • Milataxel
  • Colchiceine
UBQLN4 ubiquilin 4

Page 1 out of 1 pages